TapImmune Inc. (TPIV) Release: Presentation of HER2/neu Vaccine Development Program at Third Annual Cancer Vaccines and Active Immunity Summit, Boston, June 27-29, 2012

SEATTLE, June 26, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc (TPIV) has announced it will present a poster at the Third Annual Cancer Vaccines and Active Immunotherapy Summit in Boston describing it's HER2/Neu vaccine development program. This will include scientific details describing and differentiating this vaccine program from others in clinical development. The prime and boost approach utilizes multiple antigen technologies, licensed from the Mayo clinic, combined with TAP expression technologies developed at TapImmune. The Class II antigen pool is currently being evaluated in a phase I safety and immunogenicity study at the Mayo Clinic.